- Home
- DSP vs SKYE Comparison
DSP vs SKYE Comparison
Compare DSP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- SKYE
- Stock Information
- Founded
- DSP 1999
- SKYE 2012
- Country
- DSP United States
- SKYE United States
- Employees
- DSP N/A
- SKYE N/A
- Industry
- DSP EDP Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- SKYE Health Care
- Exchange
- DSP Nasdaq
- SKYE Nasdaq
- Market Cap
- DSP 167.4M
- SKYE 172.9M
- IPO Year
- DSP 2021
- SKYE N/A
- Fundamental
- Price
- DSP $10.59
- SKYE $5.24
- Analyst Decision
- DSP Strong Buy
- SKYE Strong Buy
- Analyst Count
- DSP 5
- SKYE 5
- Target Price
- DSP $11.80
- SKYE $18.40
- AVG Volume (30 Days)
- DSP 72.2K
- SKYE 142.7K
- Earning Date
- DSP 11-04-2024
- SKYE 11-09-2024
- Dividend Yield
- DSP N/A
- SKYE N/A
- EPS Growth
- DSP N/A
- SKYE N/A
- EPS
- DSP N/A
- SKYE N/A
- Revenue
- DSP $243,250,000.00
- SKYE N/A
- Revenue This Year
- DSP $19.71
- SKYE N/A
- Revenue Next Year
- DSP $12.84
- SKYE N/A
- P/E Ratio
- DSP N/A
- SKYE N/A
- Revenue Growth
- DSP 20.25
- SKYE N/A
- 52 Week Low
- DSP $4.98
- SKYE $1.44
- 52 Week High
- DSP $12.36
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- DSP 51.33
- SKYE 42.33
- Support Level
- DSP $10.50
- SKYE $5.71
- Resistance Level
- DSP $11.03
- SKYE $7.11
- Average True Range (ATR)
- DSP 0.39
- SKYE 0.60
- MACD
- DSP 0.02
- SKYE -0.08
- Stochastic Oscillator
- DSP 55.74
- SKYE 10.00
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.